Altered Urinary Release of Inositol Phosphoglycan A-Type in Women with Gestational Diabetes Mellitus

Scioscia, Marco; Kunjara, Sirilaksana; Gumaa, K.A.; Galán, Antonio Maiques; McLean, Patricia; Rodeck, Charles H.; Rademacher, Thomas W.

doi:10.1159/000106494

Cited by 10 publications

(5 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effects of GDM on urinary excretion of free MI and DCI in the present study differ to those reported for urinary elimination of inositol-containing phosphoglycans in fasting urine samples from late pregnancy. In GDM, urinary excretion of DCI-IPG at 26 to 30 weeks’ gestation was significantly greater than the value for normal pregnancy, 28,29 and the average urinary elimination of MI-IPG was significantly lower than the mean for normal pregnancy. 28 However, caution should be exercised when drawing a comparison to our study.…”

Section: Discussionmentioning

confidence: 65%

Urinary Excretion of Myo-Inositol and D-Chiro-Inositol in Early Pregnancy Is Enhanced in Gravidas With Gestational Diabetes Mellitus

et al. 2016

View full text Add to dashboard Cite

The effects of gestational diabetes mellitus (GDM) were determined on urinary excretion of putative components of insulin signaling. Random urine samples were collected from 375 gravidas at 6 to 14 weeks' gestation, 22 to 32 weeks' gestation, and ∼6 weeks' postpartum. Gestational diabetes mellitus developed in 35 women who were matched with 59 normal gravidas. Urinary concentrations of myo-inositol (MI) and D-chiro-inositol (DCI) were measured by gas chromatography/mass spectrometry and normalized to creatinine levels. Compared to postpartum values, urinary excretion of MI and DCI was increased 2.9-fold and 2-fold, respectively, in early pregnancy, and 5.5-fold and 4.5-fold, respectively, in later gestation. Gravidas with GDM had significantly greater MI and DCI excretion than controls in the first trimester but not subsequently. The results suggest that gravidas destined to develop GDM have altered synthesis, metabolism, and/or renal excretion of MI and DCI in early pregnancy.

show abstract

Section: Discussionmentioning

confidence: 65%

Urinary Excretion of Myo-Inositol and D-Chiro-Inositol in Early Pregnancy Is Enhanced in Gravidas With Gestational Diabetes Mellitus

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The same authors observed a positive association between DCI urinary excretion and poor glycaemic control in the second trimester of pregnancy . On the contrary, they observed that a poorer glycaemic control resulted in a reduction on Myo urinary content . The authors argue that increased DCI production/excretion, as well as the reduced Myo urine content, could represent a compensatory reaction to the hyperinsulinaemic state, rather than a primary effect mediated by insulin resistance.…”

Section: Inositol Molecular and Metabolic Aspectsmentioning

confidence: 95%

Inositol and antioxidant supplementation: Safety and efficacy in pregnancy

Formoso

Baldassarre

Ginestra

et al. 2019

Diabetes Metabolism Res

View full text Add to dashboard Cite

Summary Pregnancies complicated by diabetes have largely increased in number over the last 50 years. Pregnancy is characterized by a physiologic increase in insulin resistance, which, associated with increased oxidative stress and inflammations, could induce alterations of glucose metabolism and diabetes. If not optimally controlled, these conditions have a negative impact on maternal and foetal outcomes. To date, one can resort only to diet and lifestyle to treat obesity and insulin resistance during pregnancy, and insulin remains the only therapeutic option to manage diabetes during pregnancy. However, in the last years, in a variety of experimental models, inositol and antioxidants supplementation have shown insulin‐sensitizing, anti‐inflammatory, and antioxidant properties, which could be mediated by some possible complementary mechanism of action. Different isomers and multiple combinations of these compounds are presently available: Aim of the present review article is to examine the existing evidence in order to clarify and/or define the effects of different inositol‐ and antioxidant‐based supplements during pregnancy complicated by insulin resistance and/or by diabetes. This could help the clinician's evaluation and choice of the appropriate supplementation regimen.

show abstract

“…In addition, inositol (either in the DCI or MI isoform) has been reported to mediate glucose uptake by improving insulin sensitivity. Insulin‐mimetic effects of MI or its isomers seem to be derived from inositol phosphoglycan (IPG) which contains MI or DCI 13 . IPG acts as a second messenger in insulin signaling pathways and plays a vital role in the activation of enzymes involved in glucose uptake and utilization 14 .…”

Section: Introductionmentioning

confidence: 99%

“…Insulin-mimetic effects of MI or its isomers seem to be derived from inositol phosphoglycan (IPG) which contains MI or DCI. 13 IPG acts as a second messenger in insulin signaling pathways and plays a vital role in the activation of enzymes involved in glucose uptake and utilization. 14 Different rates of IPG imbalance have been observed in patients with diabetes and obesity.…”

Section: Introductionmentioning

confidence: 99%

Inositol supplementation and body mass index: A systematic review and meta‐analysis of randomized clinical trials

Zarezadeh

Dehghani

Faghfouri

et al. 2021

Obesity Science & Practice

View full text Add to dashboard Cite

Background: Inositol is a sugar-alcohol and recognized as a key component of cell membrane phospholipids. It has crucial role in the cell signaling pathways and contribute to improving glycemic responses. Although some earlier studies have revealed the effect of inositol mediating glucose uptake by improving insulin sensitivity, the benefit of inositol supplementation in patients with overweight and obesity is not completely understood. This study aimed to assess the impact of inositol supplementation on body mass index (BMI) through a systematic review and meta-analysis of controlled clinical trials. Methods:A systematic search was performed to August 2021 in the following databases: PubMed-Medline, Embase, Web of Science and Scopus. Fifteen controlled clinical trials investigating the effect of inositol on adult's BMI were finally included in the study. A random-effects model was employed to estimate the effect size.Subgroup analysis was performed by dose, duration, age, type of inositol. Metaregression was used to investigate presence of any linear relationship. Begg's and Egger's tests were carried out to detect small study effect. Results:The results of pooled analysis showed that inositol supplementation significantly decreased BMI scores (WMD = −0.41 kg/m 2 ; 95% CI: −0.78, −0.04; p = 0.028). Subgroup analysis was performed to identify the source of heterogeneity among studies (I 2 = 73.9%, p < 0.001), demonstrating supplementation duration, baseline BMI, mean age of participants, type of inositol and dosage were potential Meysam Zareadeh and Azadeh Dehghani have contributed equally to this work and share first authorship.This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

Altered Urinary Release of Inositol Phosphoglycan A-Type in Women with Gestational Diabetes Mellitus

Cited by 10 publications

References 52 publications

Urinary Excretion of Myo-Inositol and D-Chiro-Inositol in Early Pregnancy Is Enhanced in Gravidas With Gestational Diabetes Mellitus

Urinary Excretion of Myo-Inositol and D-Chiro-Inositol in Early Pregnancy Is Enhanced in Gravidas With Gestational Diabetes Mellitus

Inositol and antioxidant supplementation: Safety and efficacy in pregnancy

Inositol supplementation and body mass index: A systematic review and meta‐analysis of randomized clinical trials

Contact Info

Product

Resources

About